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SUMMARY
Author Manuscript

Several pathogens have been associated with increased cardiovascular disease (CVD) risk.
Whether this occurs with Mycobacterium tuberculosis infection is unclear. We assessed if
tuberculosis disease increased the risk of acute myocardial infarction (AMI). We identified
patients with tuberculosis index claims from a large de-identified database of ~15 million adults
enrolled in a U.S. commercial insurance policy between 2008 and 2010. Tuberculosis patients
were 1:1 matched to patients without tuberculosis claims using propensity scores. We compared
the occurrence of index AMI claims between the tuberculosis and non-tuberculosis cohorts using
Kaplan–Meier curves and Cox Proportional Hazard models. Data on 2026 patients with
tuberculosis and 2026 propensity-matched patients without tuberculosis were included. AMI was
more frequent in the tuberculosis cohort compared with the non-tuberculosis cohort, 67 (3·3%) vs.
32 (1·6%) AMI cases, respectively, P < 0·01. Tuberculosis was associated with an increased risk of
AMI (adjusted hazard ratio (HR) 1·98, 95% confidence intervals (CI) 1·3–3·0). The results were
similar when the analysis was restricted to pulmonary tuberculosis (adjusted HR 2·43, 95% CI
1·5–4·1). Tuberculosis was associated with an increased risk of AMI. CVD risk assessment should
be considered in tuberculosis patients. Mechanistic studies of tuberculosis and CVD are warranted.
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INTRODUCTION
The burden of tuberculosis and cardiovascular disease (CVD) is enormous worldwide [1, 2].
Tuberculosis and CVD may not only occur concomitantly, but also affect the risk of one
another. Potential contributors to CVD risk in tuberculosis may include a direct effect of
Mycobacterium tuberculosis on the myocardium and coronary arteries, increased immune
activation and cytokine production, and cross-reactivity of anti-mycobacterial antibodies
against cardiovascular tissue [3].
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We used a registry of ~15 million persons enrolled in a U.S. commercial insurance policy
representing 1 284 681 prescribers and 3631 health care provider designations from all
geographic U.S. regions [4], to determine whether tuberculosis increased the risk of acute
myocardial infarction (AMI) after adjusting for traditional CVD risk factors.

METHODS
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We identified patients with and without an index tuberculosis disease claim (International
Classification of Diseases, ninth revision (ICD-9) codes, 010·0–018·9) between 2008 and
2010. We included patients aged 25 years or older who had complete administrative data.
Younger patients were excluded due to much lesser likelihood of AMI occurrences. We
excluded patients with human immunodeficiency virus (HIV)/AIDS (acquired immune
deficiency syndrome) claims (ICD-9 code, 042) and organ or tissue transplantation claims
(ICD-9 codes, V42·0–V42·9) as both tuberculosis and AMI could manifest very differently
in these populations. Tuberculosis patients were required not to have a tuberculosis claim the
year prior, to improve likelihood of selection for new tuberculosis diagnoses within the study
period. Patients with claims related to latent tuberculosis infection (ICD-9 codes, 795·5,
795·51, 795·52) and/or non-tuberculous mycobacterial infections (ICD-9 codes, 030·0–
031·9) were excluded from the study.
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We then identified patients without tuberculosis claims to establish a comparison cohort. We
used propensity scores for 1:1 matching of tuberculosis and non-tuberculosis patients based
on the nearest neighbor method with a caliper width set at 0·2 [5]. To calculate propensity
scores, we included candidate risk factors for both tuberculosis and AMI. Thus, propensity
scores were created through a logistic regression for the predicted probability of having a
tuberculosis claim as a function of birth year, sex, race, hypertension (ICD-9 codes, 401·0–
401·9), diabetes (ICD-9 codes, 250·0–250·9), hyperlipidemia (ICD-9 codes, 272·0–272·9),
obesity (ICD-9 codes, 270·0–270·9), tobacco use (ICD-9 code, 305·1), chronic kidney
disease (ICD-9 code, 585·9) and major autoimmune condition which included ICD-9 codes
for systemic lupus erythematosus (710·0), rheumatoid arthritis and other inflammatory
polyarthropathies (714·0–714·9), psoriasis (696·0–696·8), Crohn’s disease (555·0–555·9),
and ulcerative colitis (556·0–556·9).
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We set the date of index tuberculosis claim as the start date for each tuberculosis and nontuberculosis-matched pair, and looked for the occurrence of index AMI claims (ICD-9
codes, 410·0–410·9) within the following year period. Thus patients were followed through
to the date of index AMI claim, death, insurance disenrollment or completion of 1-year
period, whichever happened first. Dates available in the study database included information
on month and year therefore we rounded all dates to the first day of their corresponding
month and year. To better assess the timing of index AMI claim in relation to the index
tuberculosis claim, we excluded those pairs where an AMI index claim was first reported
within the same month of the index tuberculosis claim. Patients with an index AMI claim
were required not to have an AMI claim the year prior to their follow-up start date, to
improve likelihood of selection for new AMI diagnoses within the study period.
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Baseline characteristics of the matched cohorts were compared using χ2 tests to ensure there
were no residual significant differences. We used the Kaplan–Meier method to estimate the
proportion of patients free of AMI over time. The log-rank test was used to compare
differences in AMI between cohorts. Cox Proportional Hazards models for paired data were
used to assess tuberculosis as a risk factor for AMI after adjusting for the other risk factors.
The results of Cox models were presented as hazard ratios (HR) accompanied by 95%
confidence intervals (CI). All analyses were performed using Stata software (version 12·0;
StataCorp, Texas, USA) with P < 0·05 as the level of statistical significance. This project
was exempt of institutional review board review as it involved the analysis of available,
existing, de-identified data.

RESULTS
Author Manuscript

Data on 2026 patients with tuberculosis and 2026 propensity score-matched patients without
tuberculosis were included in the study. There were no significant differences between the
tuberculosis and non-tuberculosis cohorts in terms of age ⩾65 years (56·9% vs. 57·3%,
P=0·78), male sex (43·7% vs. 43·5%, P = 0·89), black race (17·7% vs. 17·3%, P= 0·74);
Hispanic ethnicity (3·9% vs. 4·2%, P = 0·63), diabetes mellitus (50·3% vs. 50·5%, P = 0·88),
hypertension (65·3% vs. 64·7%, P = 0·72), hyperlipidemia (56·3% vs. 55·9%, P = 0·83),
obesity (16·2% vs. 15·2%, P = 0·34), tobacco use (17·3% vs. 17·8%, P = 0·65), chronic
kidney disease (16·9% vs. 16·7%, P = 0·87), or major autoimmune disease (19·8% vs.
19·6%, P = 0·87), indicating sufficient propensity score matching.
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There were more cases of AMI in the tuberculosis cohort (67 cases, 3·3%) than the nontuberculosis cohort (32 cases, 1·6%), P < 0·01. The Kaplan–Meier survival curves are shown
in Figure 1 (log-rank test, P < 0·01). The risk of developing AMI in patients with
tuberculosis claims was higher compared with patients without tuberculosis claims and
similar baseline characteristics and comorbidities (adjusted HR 1·98, 95% CI 1·3–3·0). The
proportional hazards assumption was not violated based on the Schoenfeld residuals test, P =
0·25. The results were similar when the analysis was restricted to pulmonary tuberculosis
claims (adjusted HR 2·43, 95% CI 1·5–4·1). Hypertension (adjusted HR 1·91, 95% CI 1·1–
3·6), chronic kidney disease (adjusted HR 2·68, 95% CI 1·7–4·2), and tobacco use (adjusted
HR 1·6, 95% CI 1·1–2·6) were independently associated with AMI.
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DISCUSSION
In this propensity score-matched analysis of commercially insured U.S. patients with
multiple comorbidities, we showed that tuberculosis disease was associated with an
approximate twofold increased risk of AMI by 1 year after a tuberculosis disease index
claim. Similar results were obtained when the analysis was restricted to pulmonary
tuberculosis.
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Our findings are consistent with a large population-based retrospective cohort study
conducted in Taiwan which showed a 1·4-fold increased subsequent risk of acute coronary
syndrome (ACS), a composite outcome that includes unstable angina and AMI diagnoses,
among patients with a history of tuberculosis disease [6]. The Taiwan study showed higher
incidence rate ratios of ACS between tuberculosis and non-tuberculosis patients when
comorbidities such as hypertension, diabetes, or hyperlipidemia were present. Therefore, we
reason that our higher risk estimate may be explained by the overall higher frequency of
traditional CVD risk factors in our population as compared with the Taiwan study. In
addition, the Taiwan study looked at ACS, whereas we focused our analysis on AMI only.
Notably, a similar analysis of the Taiwan national registry showed a 1·5-fold increased risk
of ischemic stroke among persons with a history of tuberculosis [7], which indicates that the
effect of tuberculosis in atherosclerotic disease goes beyond coronary heart disease. A major
strength of our study was the use of propensity score matching to control for demographics
and available information on relevant comorbidities among patients with and without
tuberculosis, allowing a more accurate analysis of the relationship between tuberculosis and
AMI.
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Numerous intracellular pathogens that establish chronic and/or latent infection have been
implicated in the development of CVD; i.e. HIV, cytomegalovirus, and Chlamydia
pneumoniae [8]. The connection between infection and CVD centers on several mechanisms
including direct cellular infection and damage, increased immune activation, or induction of
autoimmunity [9]. Atherogenesis and plaque rupture are, in part, dependent on the role of
activated monocytes/macrophages and Th1 effector cells releasing interferon-γ,
interleukin-1, and other cytokines [10]. Patients with tuberculosis share this proinflammatory profile of activated monocyte/macrophages, T cells and elevated inflammatory
cytokines [3]. Tuberculosis may also induce autoimmunity through molecular mimicry of
the heat shock protein (HSP) system. Antibodies to mycobacterial HSP65 may cross-react
with human HSP60, as studies indicate that antibodies to HSP65 correlate with the
development of atherosclerosis [11]. Cases of sudden cardiac death and arteritis suggested a
direct effect of M. tuberculosis on the myocardium and coronary arteries but these seem to
be rare occurrences [12].
There are a number of factors that may affect the conclusions of this study. We could not
obtain detailed information on the length of time or severity of comorbidities such as
hypertension, diabetes, renal disease, or autoimmune disorders, which could affect the risk
of AMI differently. Quantification of tobacco use or body mass index for each patient was
not available. However, we captured diagnostic codes for tobacco use and obesity as proxies.
This database has been used for analyses of fungal and mycobacterial infections including
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tuberculosis showing patterns consistent with what has been reported in the literature [4].
However, because tuberculosis is managed at local U.S. health departments, we could not
further confirm tuberculosis diagnoses or access anti-tuberculosis treatment data for our
study population. Most tuberculosis patients included in the study would be expected to be
taking anti-tuberculosis medications within a year of their first tuberculosis insurance claim.
This could be of importance, as rifamycin-containing regimens could decrease the
effectiveness of drugs used to treat traditional CVD risk factors such as hypertension,
diabetes and hyperlipidemia, and thereby increase the risk of AMI. The incidence of AMI in
the non-tuberculosis group (1·6%) was 1·5–2 times higher than the expected incidence of
AMI in a U.S. population with similar age and sex distribution [13]. This suggests that some
of the AMI events extracted from the study registry could have been prevalent cases; or that
our study population was at an overall higher risk for CVD than the general population, as
suggested by the presence of multiple comorbidities in our population. As with all
administrative databases there may be significant biases and/or errors in coding and
reporting though we have no reason to suspect they would be channeled in one direction or
another. Finally, it is important to mention that our results are not necessarily generalizable
to uninsured populations or settings where tuberculosis is highly endemic. Since the
prevalence of CVD and CVD risk factors is rising globally, research is greatly needed to
determine whether tuberculosis would have a similar effect over AMI in populations that are
traditionally more vulnerable to tuberculosis (i.e. homeless individuals, intravenous drug
users, alcohol users, persons who live in poverty and resource-constraint settings).
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In conclusion, tuberculosis was associated with an approximate twofold increased risk of
AMI in this commercially insured U.S. population with multiple comorbidities. These
findings suggest that CVD assessment should be considered in tuberculosis patients. Our
results need further validation in longitudinal studies that control for CVD risk factors in
greater detail. Further mechanistic studies of tuberculosis and CVD are warranted.

Acknowledgments
C.J.F. has received research support to the University of Cincinnati from Gilead, Pfizer, BMS, ViiV, Janssen, and
Merck. This research was supported in part by the National Center for Research Resources and the National Center
for Advancing Translational Sciences, National Institutes of Health (NIH), through Grant UL1TR000117 (MAH).
The authors would like to thank Darren Henderson, database administrator at the University of Kentucky Center for
Clinical and Translational Science for extracting and providing the data for this project.

References

Author Manuscript

1. World Health Organization. Global Status Report on Nonconcommunicable Diseases 2014. Geneva,
Switzerland: WHO; 2014.
2. World Health Organization. Global Tuberculosis Report 2015. Geneva, Switzerland: WHO; 2015.
3. Huaman MA, et al. Tuberculosis and cardiovascular disease: linking the epidemics. Tropical
Diseases, Travel Medicine and Vaccines. 2015; 1:10, 1–7.
4. Salt E, et al. Risk factors for targeted fungal and mycobacterial infections in patients taking tumor
necrosis factor inhibitors. Arthritis & Rheumatology. 2016; 68:597–603. [PubMed: 26474379]
5. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in
means and differences in proportions in observational studies. Pharmaceutical Statistics. 2011;
10:150–161. [PubMed: 20925139]

Epidemiol Infect. Author manuscript; available in PMC 2018 May 01.

HUAMAN et al.

Page 6

Author Manuscript
Author Manuscript

6. Chung WS, et al. Tuberculosis increases the subsequent risk of acute coronary syndrome: a
nationwide population-based cohort study. International Journal of Tuberculosis and Lung Disease.
2014; 18:79–83. [PubMed: 24365557]
7. Sheu JJ, et al. Tuberculosis and the risk of ischemic stroke: a 3-year follow-up study. Stroke. 2010;
41:244–249. [PubMed: 20035070]
8. Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: update on the potential contribution of
multiple infectious organisms to the pathogenesis of atherosclerosis. Thrombosis and Haemostasis.
2011; 106:858–867. [PubMed: 22012133]
9. Epstein SE, et al. Insights into the role of infection in atherogenesis and in plaque rupture.
Circulation. 2009; 119:3133–3141. [PubMed: 19546396]
10. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. New England Journal of
Medicine. 2005; 352:1685–1695. [PubMed: 15843671]
11. Xu Q, et al. Association of serum antibody to heat-shock protein 65 with carotid atherosclerosis.
Lancet. 1993; 341:255–259. [PubMed: 8093914]
12. Liu A, Hu Y, Coates A. Sudden cardiac death and tuberculosis – how much do we know?
Tuberculosis (Edinb). 2012; 92:307–313. [PubMed: 22405969]
13. Mozaffarian D, et al. Heart disease and stroke statistics-2016 update: a report from the American
Heart Association. Circulation. 2016; 133:e38–e360. [PubMed: 26673558]

Author Manuscript
Author Manuscript
Epidemiol Infect. Author manuscript; available in PMC 2018 May 01.

HUAMAN et al.

Page 7

Author Manuscript
Author Manuscript

Fig. 1.

Kaplan–Meier curves for acute myocardial infarction in the study groups.
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